Sign Out
No drug interaction studies have been conducted with Nanoxel. The metabolism of paclitaxel is catalyzed by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. In the absence of formal clinical drug interaction studies, caution should be exercised when administering Nanoxel concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4. (See Pharmacology under Actions).
Potential interactions between paclitaxel, a substrate of CYP3A4 and protease inhibitors (ritonavir, saquinavir, indinavir and nelfinavir) which are substrates and/or inhibitors of CYP3A4 have not been evaluated in clinical trials.
Continue with Google